Premium
Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy
Author(s) -
Kimura S.,
Inoguchi T.,
Yokomizo H.,
Maeda Y.,
Sonoda N.,
Takayanagi R.
Publication year - 2012
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/j.1463-1326.2012.01566.x
Subject(s) - pravastatin , albuminuria , medicine , microalbuminuria , pitavastatin , urology , diabetic nephropathy , renal function , creatinine , endocrinology , type 2 diabetes , gastroenterology , diabetes mellitus , statin , cholesterol
The effect of pitavastatin and pravastatin treatment on renal function was compared in type 2 diabetic patients with nephropathy in a randomized, controlled, open‐label, parallel and multi‐centre study. Type 2 diabetic patients with modest renal impairment (serum creatinine level <1.4 mg/dl) accompanied by albuminuria (30–600 mg/g creatinine) were randomly assigned to receive 2 mg of pitavastatin (n = 44) or 10 mg of pravastatin (n = 43) for 12 months. At 12 months, pitavastatin significantly reduced urinary albumin‐to‐creatinine ratio than pravastatin in subjects with macroalbuminuria (−67.2% vs. +14.5%, p = 0.0040), but not in subjects with microalbuminuria. There was no significant difference in the change in estimated glomerular filtration rate between the two groups. Pitavastatin is more effective than pravastatin for the reduction of albuminuria in type 2 diabetic patients with early stage of diabetic nephropathy.